Cyprium Therapeutics, Inc.

About Cyprium Therapeutics, Inc.

Cyprium Therapeutics, Inc., a Fortress Biotech company, is dedicated to developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders, with a focus on rare pediatric diseases.

Products & Services

CUTX-101 (Copper Histidinate):A product candidate under investigation for the treatment of Menkes disease and related copper metabolism disorders.

AAV-ATP7A Gene Therapy:A development pathway for gene therapy aimed at treating Menkes disease.

Specialties

Therapeutics for rare pediatric diseases Menkes disease treatment Copper metabolism disorders Gene therapy development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 4100000 MR: - FA: 4.1 million FAN: 4100000	D: 2024-03-04 FD: 2024-03-04	1 investors

Grant Latest

2024-03-04

$4.1M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Lindsay A. Rosenwald

Executive Chairman of the Board of Directors

L

Lung S. Yam

Chief Executive Officer and Director

M

Michael Weiss

Director

Recent News